
Opinion|Videos|June 12, 2024
Treatment Decisions in R/R CLL
A medical oncologist provides a comprehensive overview of treatment options for patients with relapsed/refractory chronic lymphocytic leukemia, including BTK inhibitors and CAR T-cell therapy.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- For patients with R/R disease, please discuss your approach to treatment.
- How do you choose between BTKi in the R/R setting (please provide brief, high-level overview of the data for patients)?
- Zanubrutinib vs ibrutinib (
ALPINE Extended Follow-up ASH 2023 (Brown NEJM 2023 ) - Acalabrutinib vs ibruitinib(
ELEVATE-RR Byrd J Clin Oncol, 2021 ) (ELEVATE RR 4-year Follow-up - What is the role forvenetoclax in the R/R Setting?
- If a patient fails on one treatment, how do you approach sequencing decisions?
Advertisement
Related to this article

Vicki McGrath, a Bay Area Cancer Connections board member, talks about fatigue, fear of movement and the role of peer support in post-surgery exercise.

At its 23rd annual conference, Bay Area Cancer Connections described how donations and volunteers fund services for people facing cancer’s medical, financial and practical costs.

On World Pancreatic Cancer Day, here are five numbers from the American Cancer Society's 2026 report that people with pancreatic cancer and their families should understand, and what those numbers can and cannot say about one person's outlook.

Rasonque (daraxonrasib), the first approved drug to directly target RAS in pancreatic cancer, nearly doubled survival in a key trial. Two patients, a caregiver and the professionals who care for people like them explain what it means to live with the disease.

Colleen Carvalho, chief mission officer at Bay Area Cancer Connections, explains the emotional and practical needs that often go unaddressed after a diagnosis.

Claudine Joseph, board president of Bay Area Cancer Connections, shares her mother’s breast cancer experience and why peer support matters for all patients.

Hot flashes are common during and after breast and prostate cancer treatment. Here is how hormone treatments compare with the nonhormonal medicines, therapies and comfort steps that national guidelines list, and why the right choice depends on your cancer.
Advertisement
Advertisement
Trending on CURE
1
Pregnancy After Cancer: More Survivors Are Giving Birth
2
How Areola Tattooing Can Help Breast Cancer Survivors After Reconstruction
3
A Couple Faces Bladder Cancer Together, With a Nurse as Care Partner
4
Living With a New RAS-Targeted Drug for Pancreatic Cancer
5



